Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

Landgren O., Weisel K., Rosinol L., Touzeau C., Turgut M., Hajek R., ...More

BRITISH JOURNAL OF HAEMATOLOGY, vol.198, no.6, pp.988-993, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 198 Issue: 6
  • Publication Date: 2022
  • Doi Number: 10.1111/bjh.18233
  • Journal Name: BRITISH JOURNAL OF HAEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.988-993
  • Keywords: relapsed or refractory multiple myeloma, proteasome inhibitor, carfilzomib, cytogenetics, CARFILZOMIB, DEXAMETHASONE
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.